MX2023002182A - Analogos de ham15-52 con potencia mejorada de receptor de amilina (hamy3r). - Google Patents

Analogos de ham15-52 con potencia mejorada de receptor de amilina (hamy3r).

Info

Publication number
MX2023002182A
MX2023002182A MX2023002182A MX2023002182A MX2023002182A MX 2023002182 A MX2023002182 A MX 2023002182A MX 2023002182 A MX2023002182 A MX 2023002182A MX 2023002182 A MX2023002182 A MX 2023002182A MX 2023002182 A MX2023002182 A MX 2023002182A
Authority
MX
Mexico
Prior art keywords
sub
hamy3r
ham
analogues
amylin receptor
Prior art date
Application number
MX2023002182A
Other languages
English (en)
Spanish (es)
Inventor
Søren Ljungberg Pedersen
Jens Christian Frøslev Nielsen
Kristoffer Tobias Gustav Rigbolt
Esben Matzen Bech
Morten Lundh
Paola Magotti
Borja Ballarín-González
Niels Vrang
Original Assignee
Gubra As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=72659001&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2023002182(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gubra As filed Critical Gubra As
Publication of MX2023002182A publication Critical patent/MX2023002182A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MX2023002182A 2020-09-24 2021-09-23 Analogos de ham15-52 con potencia mejorada de receptor de amilina (hamy3r). MX2023002182A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20198117 2020-09-24
PCT/EP2021/076250 WO2022063925A1 (en) 2020-09-24 2021-09-23 Ham15-52 analogues with improved amylin receptor (hamy3r) potency

Publications (1)

Publication Number Publication Date
MX2023002182A true MX2023002182A (es) 2023-11-16

Family

ID=72659001

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023002182A MX2023002182A (es) 2020-09-24 2021-09-23 Analogos de ham15-52 con potencia mejorada de receptor de amilina (hamy3r).

Country Status (21)

Country Link
US (2) US12139520B2 (https=)
EP (1) EP4021929B1 (https=)
JP (1) JP2023544959A (https=)
KR (1) KR20230073176A (https=)
CN (1) CN116322741A (https=)
AU (1) AU2021350396A1 (https=)
BR (1) BR112023002525A2 (https=)
CA (1) CA3189267A1 (https=)
DK (1) DK4021929T5 (https=)
ES (1) ES2950137T3 (https=)
FI (1) FI4021929T3 (https=)
HR (1) HRP20230534T1 (https=)
HU (1) HUE062560T2 (https=)
IL (1) IL300620B2 (https=)
MX (1) MX2023002182A (https=)
PL (1) PL4021929T3 (https=)
PT (1) PT4021929T (https=)
RS (1) RS64256B1 (https=)
SI (1) SI4021929T1 (https=)
WO (1) WO2022063925A1 (https=)
ZA (1) ZA202301635B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI815327B (zh) 2021-03-03 2023-09-11 美商美國禮來大藥廠 長效澱粉素受體促效劑及其用途
IL317600B2 (en) 2022-07-01 2026-03-01 Gubra As Amylin receptor (HAMY3R) agonists with improved chemical stability
TW202540155A (zh) 2023-11-30 2025-10-16 丹麥商諾佛 儂迪克股份有限公司 Glp-1、gip及澱粉素受體之三重促效劑

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5288931A (en) * 1991-12-06 1994-02-22 Genentech, Inc. Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation
GB9912350D0 (en) * 1999-05-26 1999-07-28 European Molecular Biology Lab Embl Modified cytokine
FI117667B (fi) * 2001-07-05 2007-01-15 Univ Zuerich Farmaseuttinen koostumus, joka soveltuu käytettäväksi ortopediassa ja hammaslääketieteessä
NZ579621A (en) * 2004-02-11 2011-03-31 Amylin Pharmaceuticals Inc Hybrid polypeptides with selectable properties
WO2007022123A2 (en) 2005-08-11 2007-02-22 Amylin Pharmaceuticals, Inc. Hybrid polypeptides with selectable properties
AU2012212047A1 (en) * 2011-02-03 2013-08-22 Xoma Technology Ltd. Methods and materials for enhancing functional protein expression in bacteria
JP6121992B2 (ja) 2011-06-10 2017-04-26 ノヴォ ノルディスク アー/エス ポリペプチド
AR097701A1 (es) * 2013-09-19 2016-04-13 Zealand Pharma As Análogos de amilina
BR112017019378A2 (pt) 2015-03-18 2019-02-19 Zealand Pharma A/S análogos de amilina
WO2019005623A1 (en) 2017-06-30 2019-01-03 Adepthera Llc PEPTIDE ANALOGS
AR116632A1 (es) 2018-10-11 2021-05-26 Intarcia Therapeutics Inc Polipéptidos análogos de la amilina humana y sus métodos de uso

Also Published As

Publication number Publication date
CA3189267A1 (en) 2022-03-31
AU2021350396A1 (en) 2023-03-16
CN116322741A (zh) 2023-06-23
IL300620B2 (en) 2025-12-01
IL300620A (en) 2023-04-01
JP2023544959A (ja) 2023-10-26
ZA202301635B (en) 2024-03-27
HRP20230534T1 (hr) 2023-08-04
BR112023002525A2 (pt) 2023-04-04
WO2022063925A1 (en) 2022-03-31
KR20230073176A (ko) 2023-05-25
HUE062560T2 (hu) 2023-11-28
RS64256B1 (sr) 2023-07-31
IL300620B1 (en) 2025-08-01
US20240101634A1 (en) 2024-03-28
PL4021929T3 (pl) 2023-07-31
FI4021929T3 (fi) 2023-06-14
PT4021929T (pt) 2023-06-21
SI4021929T1 (sl) 2023-09-29
ES2950137T3 (es) 2023-10-05
DK4021929T5 (da) 2024-07-29
DK4021929T3 (da) 2023-07-10
US12139520B2 (en) 2024-11-12
EP4021929B1 (en) 2023-04-26
US20250129134A1 (en) 2025-04-24
EP4021929A1 (en) 2022-07-06

Similar Documents

Publication Publication Date Title
MX2023002182A (es) Analogos de ham15-52 con potencia mejorada de receptor de amilina (hamy3r).
Thanapluetiwong et al. Vitamin D supplement on prevention of fall and fracture: a meta-analysis of randomized controlled trials
AP1763A (en) Pulmonary administration of chemically modified insulin
Goyal et al. Neglected Monteggia fracture dislocations in children: a systematic review
PH12020551742A1 (en) Gip derivatives and uses thereof
Bermúdez de Castro et al. Early pleistocene human humeri from the gran dolina‐TD6 site (sierra de atapuerca, spain)
AR022368A1 (es) Procedimiento para administrar peptidos insulinotropicos
NO20063436L (no) Intranasal administrasjon av glukose-regulerende peptider
JOP20210089A1 (ar) نظائر بروتين تيروسين-تيروسين وطرق لاستخدامها
Rigby et al. Total glossectomy without laryngectomy–a review of functional outcomes and reconstructive principles
DK1643861T3 (da) Fiber- og kalorierig flydende næringssammensætning til tarmsundhed hos ældre patienter
Nagai et al. Growth hormone therapy and scoliosis in patients with Prader–Willi syndrome
MX2009011638A (es) Composiciones basadas en gp5 de prrsv y metodos.
Magu et al. Modified Pauwels' intertrochanteric osteotomy in neglected femoral neck fractures in children: a report of 10 cases followed for a minimum of 5 years
DE602005023342D1 (en) S (porcine reproductive und respiratory syndrome) von schweinen
Shalev et al. Another adult with Meier-Gorlin syndrome-insights into the natural history
WO2022157747A3 (en) Pharmaceutical glp peptide compositions and methods of preparation thereof
Goswami et al. Restless legs syndrome associated with use of stevia nonnutritive sweetener
Singh et al. An iatrogenic proximal radioulnar synostosis: a case report and review of literature
Chen et al. Diastolic dysfunction following HIV infection
Kumar et al. Even After Vaccination, is the Second Wave of COVID-19 in India More Dangerous?
Checcucci et al. Acute traumatic swan neck deformity: a case report of the oblique retinacular ligament lesion
NO20065627L (no) Orale produkter
Ungchusak et al. COVID-19 Thailand: Transition from “Semi-lockdown” to stability
Woolley et al. Anterior neck fat deposition in lipodystrophy syndrome; a new variant on a theme?